Seeking Alpha

More on Edwards Life Sciences (EW): Q4 beats on EPS but misses on revenue, due in large part to...

More on Edwards Life Sciences (EW): Q4 beats on EPS but misses on revenue, due in large part to the late approval of Sapien, its catheter-delivered heart valve. The device gained FDA approval in late November and saw only marginal sales impact during the quarter. Shares -4.3% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|